TEVA-PHARMACEUTICALS

Teva Pharmaceuticals Europe: Patients Search for Information Online – but Aren’t Sure If They Can Trust What They Find

Recent research commissioned1
by Teva Pharmaceuticals has
shown that patients, especially those with chronic conditions, have a
significant need for online information but they question the
reliability of some sources.1

Recent research in the professional field highlights the growing
interest by medical professionals in digital assets to support their
continuous education needs and day-to-day work. A 2017 DRG Digital
report found that millennial physicians are more reliant on digital
sources of information spending as much as three hours consulting
external digital resources including websites for healthcare
professionals. They source online medical journals and medical reference
sites far more frequently than their older peers.2

To address this professional need Teva is working with Migraine Trust
International Symposium (MTIS) to create engaging online interviews with
leaders in the field of neurology including Professor of Neurology at
King's College London and Medical Trustee of The Migraine Trust, Peter
J. Goadsby on the subject of ‘Recent advances in headache neuroimaging’.
These videos and content will be made available through the MTIS website
for UK delegates and on NeurologyBytes.com for non-UK delegates.

Neurology Bytes is a European Healthcare Professional portal initiated
by Teva Europe that hosts a variety of educational content that
complements the busy schedule of a neurologist and addresses the unmet
need for reliable and trustworthy information.

CEO and Co-Founder of Healint, Francois Cadiou commends Teva’s efforts
to provide independently reviewed information to support healthcare
professionals in becoming more knowledgeable about migraine. “Our
collaboration with Teva aims to support healthcare professionals to
understand migraine patients better, so that they can obtain the most
effective care plan faster. We at Healint are happy to support this
transformative initiative with the unique data analysis carried out on
the Healint platform. This fact-based information and our collaboration
with Teva provides significant benefits to the entire migraine
community.”

Professor of Neurology at King's College London and Medical Trustee of
The Migraine Trust, Peter J. Goadsby MD PhD stated: “Migraine is a
complex condition which requires broader disease awareness in order for
patients to communicate effectively about their condition. Patients
often need to be their own advocates given the significant amount of
patient information doctors require to diagnose and treat their
conditions. I welcome Teva’s initiatives which aim to support both the
patient and the medical community through reliable and trustworthy
information. I hope this initiative creates a better dialogue between
patients and their doctors so they can determine the best course of
treatment for this debilitating condition.”

Teva Head of Digital, Timothy White said: “Teva is committed to
empowering patients and professionals around the world through their
health journey, especially those living with or treating chronic
conditions such as migraine, by providing high quality medicines as well
as tools based on human insights. Our partnerships with MTIS and Healint
as well as the growth of our Neurologybytes.com platform demonstrate the
practical ways of how we are bringing the vision to life.”

-ENDS-

About the Research

The research (2018) found:

7 in 10 people (73%) in the UK have a chronic condition and online
resources continue to be sought with over half (58%) of UK respondents
with chronic conditions claiming to have searched for information on a
weekly or monthly basis1

People living with chronic conditions were more likely to search for
health information online on a weekly or monthly basis (58%) compared
to those without chronic conditions (44%)1

The biggest issue that the UK faces in relation to online health
information is understanding if it is trustworthy and reliable1

Search engines are the most popular online source of health
information but not the most trusted. For example, in the UK, the NHS
Choices website is the most trusted source of information with 3 out
of 4 (75%) of respondents stating they trust the site to have quality
and dependable information1

About Migraine

Migraine is an unpredictable neurological condition with symptoms such
as severe head pain and physical impairment that can impact quality of
life and productivity.3
There are two clinical manifestations
of migraine – chronic, where patients suffer 15 or more headache days
per month, and episodic, where patients have 14 or less headache days
per month.4
With more than 1 billion people affected
worldwide, migraine is the third most prevalent illness in the world.3

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global
leader in generic medicines, with innovative treatments in select areas,
including CNS, pain and respiratory. We deliver high-quality generic
products and medicines in nearly every therapeutic area to address unmet
patient needs. We have an established presence in generics, specialty,
OTC and API, building on more than a century-old legacy, with a fully
integrated R&D function, strong operational base and global
infrastructure and scale. We strive to act in a socially and
environmentally responsible way. Headquartered in Israel, with
production and research facilities around the globe, we employ 45,000
professionals, committed to improving the lives of millions of patients.
Learn more at www.tevapharm.com
.